Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00247559
Status:
COMPLETED
Last Update Posted:
2019-11-22
First Post:
2005-11-01
Brief Title:
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines Crows Feet
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
A Phase II Multi-Centre Randomised Double-blind Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15 30 or 45 Units Per Eye of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines Crows Feet
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin BoNT-A and the widespread use of the BoNT-A for cosmetic applications the number of randomised controlled clinical trials is small Much of the published information is based on open-label studies or anecdotal data Of the robust trial data that is available the vast majority relates to the treatment of glabellar lines and there is little data available regarding the use of BoNT-A in lateral canthal lines This study aims to determine the optimum dose for the use of BoNT-A in this area
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-001421-17 | EUDRACT_NUMBER | None | None |